biotech · Parkinson Disease · Amyotrophic Lateral Sclerosis · DNLI
Denali Therapeutics
Denali Therapeutics clinical programs — 0 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
161 Oyster Point Blvd, South San Francisco, California 94080, US HQ
2015 Founded
567 Employees
Public company Type
DNLI · NYSE Ticker
Company details
- Status
- Public
- HQ
- 161 Oyster Point Blvd, South San Francisco, California 94080, US
- Founded
- 2015
- Employees
- 567
- Programs
- 23
- Drugs
- 10
- Patents
- 42
Denali Therapeutics projects
0 ClinicalTrials.gov programs sponsored by Denali Therapeutics.
Denali Therapeutics has 0 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
No programs matched
Frequently asked questions
How many clinical projects does Denali Therapeutics have?
0 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.